Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Julie Cooke Sells 700 Shares

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) insider Julie Cooke sold 700 shares of Neurocrine Biosciences stock in a transaction on Monday, February 10th. The shares were sold at an average price of $118.28, for a total transaction of $82,796.00. Following the completion of the transaction, the insider now owns 18,831 shares in the company, valued at approximately $2,227,330.68. This represents a 3.58 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Julie Cooke also recently made the following trade(s):

• On Thursday, February 13th, Julie Cooke sold 1,551 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $116.78, for a total transaction of $181,125.78.
• On Friday, January 31st, Julie Cooke sold 1,740 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $152.89, for a total transaction of $266,028.60.

Neurocrine Biosciences Price Performance

Shares of NASDAQ NBIX traded down $1.85 during mid-day trading on Friday, hitting $115.02. The company's stock had a trading volume of 1,479,784 shares, compared to its average volume of 952,604. The stock has a market cap of $11.65 billion, a price-to-earnings ratio of 34.96 and a beta of 0.33. The company's fifty day simple moving average is $137.83 and its 200-day simple moving average is $130.54. Neurocrine Biosciences, Inc. has a one year low of $110.95 and a one year high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $1.00 EPS for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.45% and a net margin of 14.49%. On average, sell-side analysts predict that Neurocrine Biosciences, Inc. will post 6.53 EPS for the current year.

Hedge Funds Weigh In On Neurocrine Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in NBIX. Dodge & Cox grew its stake in shares of Neurocrine Biosciences by 134.2% in the fourth quarter. Dodge & Cox now owns 3,016,425 shares of the company's stock valued at $411,742,000 after buying an additional 1,728,605 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Neurocrine Biosciences in the fourth quarter valued at $115,193,000. Wellington Management Group LLP grew its stake in shares of Neurocrine Biosciences by 102.9% in the fourth quarter. Wellington Management Group LLP now owns 1,457,425 shares of the company's stock valued at $198,939,000 after buying an additional 739,199 shares in the last quarter. Thrivent Financial for Lutherans grew its stake in shares of Neurocrine Biosciences by 2,759.4% in the fourth quarter. Thrivent Financial for Lutherans now owns 737,772 shares of the company's stock valued at $100,705,000 after buying an additional 711,970 shares in the last quarter. Finally, State Street Corp grew its stake in shares of Neurocrine Biosciences by 11.7% in the third quarter. State Street Corp now owns 5,148,293 shares of the company's stock valued at $593,186,000 after buying an additional 539,936 shares in the last quarter. 92.59% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have commented on NBIX shares. Piper Sandler restated an "overweight" rating and issued a $160.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, December 23rd. Guggenheim dropped their price target on shares of Neurocrine Biosciences from $165.00 to $163.00 and set a "buy" rating on the stock in a research note on Monday, February 10th. Bank of America dropped their price target on shares of Neurocrine Biosciences from $184.00 to $179.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Barclays boosted their price target on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the stock an "overweight" rating in a research note on Monday, December 23rd. Finally, William Blair reiterated an "outperform" rating on shares of Neurocrine Biosciences in a research note on Friday, February 7th. Five investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $166.90.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.